Methotrexate in the combination therapy of juvenile idiopathic arthritis
https://doi.org/10.14412/1996-7012-2018-3-98-102
Abstract
The paper discusses whether biological agents (BAs) may be used as monotherapy. The combination of different BAs and methotrexate (MTX) allows a good result in patients with juvenile idiopathic arthritis refractory to standard antirheumatic therapy. The efficiency of this therapy meets the ACRpedi50 criteria in 80–90% of patients; one third of patients can achieve the inactive stage of the disease. When BAs are administered, the frequency of use of nonsteroidal anti-inflammatory drugs and glucocorticoids is reduced. In only 15% of patients, MTX can be discontinued during the first year of therapy with BA, significantly more frequently with tocilizumab.
About the Authors
E. S. Zholobova
University Children's Hospital;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Elena Spartakovna Zholobova
Department of Childhood Diseases
19, Bolshaya Pirogovskaya St., Build. 1, Moscow 101000
М. N. Nikolaeva
University Children's Hospital;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Childhood Diseases
19, Bolshaya Pirogovskaya St., Build. 1, Moscow 101000
S. N. Chebysheva
University Children's Hospital;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Childhood Diseases
19, Bolshaya Pirogovskaya St., Build. 1, Moscow 101000
A. V. Meleshkina
University Children's Hospital;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Childhood Diseases
19, Bolshaya Pirogovskaya St., Build. 1, Moscow 101000
O. Yu. Loskutova
University Children's Hospital;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Childhood Diseases
19, Bolshaya Pirogovskaya St., Build. 1, Moscow 101000
L. A. Galstyan
University Children's Hospital;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Childhood Diseases
19, Bolshaya Pirogovskaya St., Build. 1, Moscow 101000
E. Yu. Afonina
University Children's Hospital;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Childhood Diseases
19, Bolshaya Pirogovskaya St., Build. 1, Moscow 101000
References
1. Alekseeva EI, Litvitskii PF. Juvenile rheumatoid arthritis: etiology, pathogenesis, clinic, algorithms of diagnosis and treatment. In: Baranov AA, editor. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov [Guidelines for doctors, teachers, researchers]. Moscow: VEDI; 2007. 385 p.
2. Zholobova ES, Shakhbazyan IE, Ulybina OV, et al. Juvenile rheumatoid arthritis. In: Geppe NA, Podchernyaeva NS, Lyskina GA, editors. Rukovodstvo po detskoi revmatologii [Guidelines for pediatric rheumatology]. Moscow: GEOTAR-Media; 2011. P. 162-245.
3. Beukelman T1, Patkar NM, Saag KG, et al. American College of Rheumatology. Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82. doi: 10.1002/acr.20460.
4. Rodionovskaya SR, Nikishina IP. Methotrexate in the treatment of juvenile chronic arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2003;41(2):65-71. (In Russ.)]. doi: 10.14412/1995-4484-2003-772
5. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004 Apr;31(4):645-8.
6. Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2005 Feb;52(2):554-62.
7. Alsufyani K, Ortiz-Alvarez O, Cabral DA, et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004 Jan; 31(1):179-82.
8. Bazarova TM, Alekseeva EI, Vasil'eva SI, et al. Safety of use of inhibitors of tumor necrosis factors alpha in adult and pediatric rheumatology practice. Voprosy sovremennoi pediatrii. 2010;9(1):2-15. (In Russ.).
9. Nikishina IP. Soluble receptors to tumor necrosis factor (etanercept) in the treatment of juvenile arthritis. Russkii meditsinskii zhurnal. 2009;17(3):2-7. (In Russ.).
10. Otten M, Prince F, Twilt M, et al. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2010 Mar;37(3):665-7. doi: 10.3899/jrheum.090550. Epub 2010 Jan 15.
11. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with Juvenile rheumatoid arthritis. Arthritis Rheum. 2008 May;58(5):1496-504. doi: 10.1002/art.23427.
12. Alekseeva EI, Mitenko EV, Valieva SI, et al. Efficacy and safety of adalimumab therapy in children with juvenile idiopathic arthritis and uveitis. Voprosy sovremennoi pediatrii. 2012;11(1):90-7. (In Russ.).
13. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet. 2008 Mar 22;371(9617):998-1006. doi: 10.1016/S0140-6736(08)60454-7.
14. Niehues T, Lankisch P. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Paediatr Drugs. 2006;8(6):347-56.
15. Sevost'yanov VK, Zholobova ES, Melik-Guseinov DV. The structure of juvenile idiopathic arthritis according to the register of children with rheumatic diseases in Moscow. Russkii meditsinskii zhurnal. 2017;(1):6-10. (In Russ.).
Review
For citations:
Zholobova ES, Nikolaeva МN, Chebysheva SN, Meleshkina AV, Loskutova OY, Galstyan LA, Afonina EY. Methotrexate in the combination therapy of juvenile idiopathic arthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(3):98-102. (In Russ.) https://doi.org/10.14412/1996-7012-2018-3-98-102
Views:
1379
Email this article 